Jenscare Scientific Co., Ltd. (9877.HK)
HKSE · HKD · Healthcare · Medical Devices
HK$6.19 (-7.20%) as of
Key statistics
- Market cap
- 2.58B
- Forward P/E
- -35.12
- EPS (TTM)
- -0.380
- Dividend yield
- 0.00%
- 52-week range
- 5.790 – 11.980
- Beta
- 0.61
- Revenue (TTM)
- 141.29M
- Profit margin
- -106.41%
- Analyst target
- HK$9.61
- Volume
- 314.20k
About Jenscare Scientific Co., Ltd.
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People's Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; Ken-Valve, a TRVR system for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve intervention (TMVR) repair system to treat patients with severe mitral regurgitation; JensRelive, a TMVR system to treat patients with severe mitral regurgitation and replace dysfunctional primary mitral valves without undergoing routine thoracotomy surgery; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention. In addition, it offers platform technologies/accessories comprising introducer kit, JeniGal anti-calcification technology, dry-tissue technology and polymer leaflet technology; and engages in consulting and investment activities. The company was incorporated in 2011 and is headquartered in Ningbo, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Ningbo, China
- Employees
- 225
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.